eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Journal's reviewers Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
4/2021
vol. 38
 
Share:
Share:
more
 
 
abstract:
Review paper

The efficacy of Nigella sativa supplementation for asthma control: a meta-analysis of randomized controlled studies

Anqiang Han
1
,
Danqin Shi
2

1.
Department of Respiratory, Tongliang District People Hospital, Chongqing, China
2.
Department of Obstetrics, Hechuan District People Hospital, Chongqing, China
Adv Dermatol Allergol 2021; XXXVIII (4): 561–565
Online publish date: 2020/02/24
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
The efficacy of Nigella sativa supplementation for asthma control remains controversial. We have conducted a systematic review and meta-analysis to explore the influence of Nigella sativa supplementation on asthma control.

Material and methods
We have searched PubMed, EMBASE, Web of science, EBSCO, and Cochrane library databases through June 2019 for randomized controlled trials (RCTs) assessing the efficacy of Nigella sativa supplementation for asthma control.

Results
Four RCTs are included in the meta-analysis. Overall, compared with the control group for asthma, Nigella sativa supplementation is associated with the increased ACT scores (SMD = 0.50; 95% CI: 0.11–0.88; p = 0.01), and FEV1 (SMD = 1.84; 95% CI: 0.07–3.60; p = 0.04), but demonstrates no obvious impact on PEF (SMD = 3.11; 95% CI: –1.30 to 7.52; p = 0.17), IL-4 (SMD = –0.31; 95% CI: –1.21 to 0.59; p = 0.50), or IFN-γ (SMD = 1.11; 95% CI: –0.44 to 2.67; p = 0.16).

Conclusions
Nigella sativa supplementation may provide additional benefits for the treatment of asthma.

keywords:

Nigella sativa, asthma, asthma control test, randomized controlled trials

Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe